Skip to main content

Advertisement

SpringerLink
Log in

Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Background

There are no studies assessing the development of latent tuberculosis infection (LTBI) in patients on tumor necrosis factor inhibitors (TNFα-I) in high TB prevalence areas of the USA. Our objective was to assess the rate of LTBI development in rheumatoid arthritis (RA) patients on TNFα-I therapies in San Bernardino and Riverside Counties of California, high TB prevalence areas in the US.

Methods

Data were extracted from the electronic health record for 217 adult RA patients across three health centers from January 2010 to January 2017 who have had at least 1 year of TNFα-I use and negative initial QuantiFERON Gold status. Demographics, TNFα-I type, duration of use, TB risk factors, QuantiFERON results, rates of re-screening, TB test seroconversion, and its association with drug use and other factors were assessed.

Results

Of the 217 patients, 115 (53%) received baseline and annual screening for LTBI. LTBI was diagnosed in 9.4% (10) of patients. Four patients were on infliximab, three on golimumab, two on adalimumab, and one on etanercept. Hispanic patients tended to have a greater than 200% increase in odds of seroconversion compared to non-Hispanic patients. Infliximab and golimumab were associated with a 92% and 400% increase in odds of seroconversion, respectively.

Conclusion

The LTBI developed in 9.4% of the patients. This is higher than what is reported for previous US studies. Screening for LTBI in the US should take into consideration TB prevalence, ethnicity, drug type, and duration of use. For our local population and similar populations, annual screening should be practiced.

Key Points

• Although patients on TNFα inhibitor (TNFα-I) therapy are at high risk of latent tuberculosis infection (LTBI), few studies report the rate of LTBI in patients living in high prevalence areas of the US.

• The rate of LTBI was 9.4% in patients on TNFα-I therapy in Southern California. The risk of seroconversion was higher in patients of Hispanic ethnicity and also higher for those on infliximab and golimumab compared to those on other TNFα-I therapies.

• Screening guidelines for LTBI screening on TNFα-I should consider local TB prevalence, drugs used, duration of use and ethnicity for cost efficient, and optimal healthcare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21(10):2575–2579

    Article  CAS  Google Scholar 

  2. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185–1206

    Article  CAS  Google Scholar 

  3. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986–1992

    Article  CAS  Google Scholar 

  4. Cuomo G, D’Abrosca V, Iacono D, Pantano I (2017) The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 36(2):457–461

    Article  Google Scholar 

  5. Hatzara C et al (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74(10):1848–1853

    Article  CAS  Google Scholar 

  6. Data as reported to World Health Organization. Estimates of TB and MDR TB burden. Generated December 2018

  7. Tuberculosis Control Branch, Report on Tuberculosis in California, 2017. California Department of Public Health, Richmond, CA. August 2018

  8. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T, American College of Rheumatology (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68(1):1–25

    Article  Google Scholar 

  9. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M, BIOBADASER Group (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772

    Article  CAS  Google Scholar 

  10. Data from California Department of Public Health, Tuberculosis Control Branch. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/TB-Disease-Data.aspx. Accessed Jun 2019

  11. Chung J, Aronson AB, Srikantha R, Vogelgesang SA, Wanat KA (2018) Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: a retrospective cohort study identifying an important practice gap. J Am Acad Dermatol 79(1):169–171

    Article  Google Scholar 

  12. Raza S et al (2016) “Conversion rate of tuberculosis screening tests in patients with rheumatic diseases while receiving anti-tumor necrosis factor alpha agents”. American College of Rheumatology Annual Meeting Poster. September 2016

  13. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology biologics register (BSRBR). Ann Rheum Dis 69(3):522–528

    Article  CAS  Google Scholar 

  14. QuantiFERON-TB Gold ELISA Package Insert

  15. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776–781

    PubMed  Google Scholar 

  16. Redelman-Sidi G, Sepkowitz KA (2013) IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 188(4):422–431

    Article  CAS  Google Scholar 

  17. Bae W et al (2016) Comparison of the sensitivity of QuantiFERON-TB Gold in-tube and T-SPOT.TB according to patient age. PLoS One 11(6):e0156917

    Article  Google Scholar 

  18. TOCQUE K et al (1998) Long-term trends in tuberculosis. Am J Respir Crit Care Med 158(2):484–488

    Article  CAS  Google Scholar 

  19. Metcalfe JZ, Cattamanchi A, McCulloch C, Lew JD, Ha NP, Graviss EA (2013) Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 187(2):206–211

    Article  CAS  Google Scholar 

  20. Schablon A et al (2010) Serial testing with an interferon-γ release assay in German healthcare workers. GMS Krankenhhyg Interdiszip 5(2)

  21. Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S, Hopkins S, Seneviratne S, Cropley I, Lipman M (2017) Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J 50(4):1701267

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Loma Linda University Medical Center, 11234 Anderson St, Suite 1503A, Loma Linda, California, 92354, USA

    Noopur Goel

  2. Division of Rheumatology, Department of Medicine, Loma Linda University School of Medicine, 11234 Anderson St, Suite 1503A, Loma Linda, California, 92354, USA

    Karina Torralba & Christina Downey

  3. Loma Linda University School of Medicine, 11234 Anderson St, Loma Linda, California, 92354, USA

    Lorena Salto

Authors
  1. Noopur Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karina Torralba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Downey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lorena Salto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Downey.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goel, N., Torralba, K., Downey, C. et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California. Clin Rheumatol 39, 2291–2297 (2020). https://doi.org/10.1007/s10067-020-04991-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-04991-y

Keywords

Search

Navigation